Biex PMA for Salest preterm delivery test slated for second quarter 1997 submission.
This article was originally published in The Gray Sheet
Executive Summary
BIEX SALEST PRETERM PREGNANCY TEST SLATED FOR PMA SUBMISSION in the second quarter of 1997, the company says. The Salest test is designed to predict the risk of preterm delivery by measuring salivary estriol (E3), an estrogen hormone produced by the placenta and the fetoplacental unit after the ninth week of gestation.
You may also be interested in...
Fujifilm Demonstrates Health Specialism With European HealthTech Spinout
From X-ray film in 1936 to the world’s first digital X-ray system in 1983, Fujifilm has a long heritage in medical diagnostics.
Financing Quarterly Statistics, Q1 2024
During Q1, biopharmas brought in an aggregate $30.1bn in financing and device company fundraising totaled $2.8bn; while in vitro diagnostic firms and research tools players raised $724m.
Helping Organizations Deliver On KPIs And Giving Staff A Voice
ImproveWell has won awards for its software technology that allows health care staff at the sharp end of patient care to report on problems as they happen. The outcome is a real-time learning process that contributes to improved operational efficiencies for health systems, says In Vivo Rising Leader Lara Mott.